Search research articles
Contact Us
Filters
Showing results (1-10 of 38) with videos related to
Page
of 4
Sort By:
British Journal of Cancer
|
November 3, 2024
Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review
Bishma Jayathilaka, Farah Mian, Fanny Franchini, et al.
Critical Reviews in Oncology/Hematology
|
December 20, 2024
Analysis of risk factors for immune-related adverse events induced by immune checkpoint inhibitor treatment in cancer: A comprehensive systematic review
Bishma Jayathilaka, Farah Mian, Jo Cockwill, et al.
Gynecologic Oncology
|
April 1, 2014
Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS)
George Au-Yeung, Penelope M Webb, Anna DeFazio, et al.
Journal of Medical Imaging and Radiation Oncology
|
February 5, 2013
Radiation with cisplatin or carboplatin for locally advanced cervix cancer: the experience of a tertiary cancer centre
George Au-Yeung, Linda Mileshkin, David M Bernshaw, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
August 23, 2024
Innovations in Rare Gynecologic Cancer: Melanoma, Neuroendocrine, and Low-Grade Serous Ovarian
George Au-Yeung, Emily MacArthur, Joanna Chan, et al.
Frontiers in Oncology
|
June 19, 2024
Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group
Nadja Stiegeler, Dale W Garsed, George Au-Yeung, et al.
Gynecologic Oncology
|
September 14, 2018
19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes
Diar Aziz, Dariush Etemadmoghadam, C Elizabeth Caldon, et al.
Cancer Research
|
September 12, 2020
Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell Cancer
Walid J Azar, Elizabeth L Christie, Chris Mitchell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 24, 2022
Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients
Tharani Sivakumaran, Michael Krasovitsky, Alison Freimund, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 27, 2026
Comprehensive detection of genetic and epigenetic alterations in cancer using long reads with TumorLens
Luis F Paulin, Minyi Shi, Yilei Fu, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 38) with videos related to
Sort By:
Page
of 4
British Journal of Cancer
|
November 3, 2024
Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review
Bishma Jayathilaka, Farah Mian, Fanny Franchini, et al.
Critical Reviews in Oncology/Hematology
|
December 20, 2024
Analysis of risk factors for immune-related adverse events induced by immune checkpoint inhibitor treatment in cancer: A comprehensive systematic review
Bishma Jayathilaka, Farah Mian, Jo Cockwill, et al.
Gynecologic Oncology
|
April 1, 2014
Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS)
George Au-Yeung, Penelope M Webb, Anna DeFazio, et al.
Journal of Medical Imaging and Radiation Oncology
|
February 5, 2013
Radiation with cisplatin or carboplatin for locally advanced cervix cancer: the experience of a tertiary cancer centre
George Au-Yeung, Linda Mileshkin, David M Bernshaw, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
August 23, 2024
Innovations in Rare Gynecologic Cancer: Melanoma, Neuroendocrine, and Low-Grade Serous Ovarian
George Au-Yeung, Emily MacArthur, Joanna Chan, et al.
Frontiers in Oncology
|
June 19, 2024
Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group
Nadja Stiegeler, Dale W Garsed, George Au-Yeung, et al.
Gynecologic Oncology
|
September 14, 2018
19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes
Diar Aziz, Dariush Etemadmoghadam, C Elizabeth Caldon, et al.
Cancer Research
|
September 12, 2020
Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell Cancer
Walid J Azar, Elizabeth L Christie, Chris Mitchell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 24, 2022
Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients
Tharani Sivakumaran, Michael Krasovitsky, Alison Freimund, et al.
Medrxiv : the Preprint Server for Health Sciences
|
March 27, 2026
Comprehensive detection of genetic and epigenetic alterations in cancer using long reads with TumorLens
Luis F Paulin, Minyi Shi, Yilei Fu, et al.
Page
of 4